Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Antonio Passaro; Maise Al Bakir; Emily G. Hamilton; Maximilian Diehn; Fabrice André; Sinchita Roy-Chowdhuri; Giannis Mountzios; Ignacio I. Wistuba; Charles Swanton; Solange Peters

doi:10.1016/j.cell.2024.02.041

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Antonio Passaro, Maise Al Bakir, Emily G. Hamilton, Maximilian Diehn, Fabrice André, Sinchita Roy-Chowdhuri, Giannis Mountzios, Ignacio I. Wistuba, Charles Swanton, Solange Peters

Résultats de recherche: Contribution à un journal › Article 'review' › Revue par des pairs

39 Citations (Scopus)

Résumé

The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.

langue originale	Anglais
Pages (de - à)	1617-1635
Nombre de pages	19
journal	Cell
Volume	187
Numéro de publication	7
Les DOIs	https://doi.org/10.1016/j.cell.2024.02.041
état	Publié - 28 mars 2024

Accès au document

10.1016/j.cell.2024.02.041

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{9b9d8002c5da41e1a7c792e8f9cff9aa,

title = "Cancer biomarkers: Emerging trends and clinical implications for personalized treatment",

abstract = "The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.",

author = "Antonio Passaro and {Al Bakir}, Maise and Hamilton, {Emily G.} and Maximilian Diehn and Fabrice Andr{\'e} and Sinchita Roy-Chowdhuri and Giannis Mountzios and Wistuba, {Ignacio I.} and Charles Swanton and Solange Peters",

note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Inc.",

year = "2024",

month = mar,

day = "28",

doi = "10.1016/j.cell.2024.02.041",

language = "English",

volume = "187",

pages = "1617--1635",

journal = "Cell",

issn = "0092-8674",

number = "7",

}

TY - JOUR

T1 - Cancer biomarkers

T2 - Emerging trends and clinical implications for personalized treatment

AU - Passaro, Antonio

AU - Al Bakir, Maise

AU - Hamilton, Emily G.

AU - Diehn, Maximilian

AU - André, Fabrice

AU - Roy-Chowdhuri, Sinchita

AU - Mountzios, Giannis

AU - Wistuba, Ignacio I.

AU - Swanton, Charles

AU - Peters, Solange

PY - 2024/3/28

Y1 - 2024/3/28

N2 - The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.

AB - The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85188420233&partnerID=8YFLogxK

U2 - 10.1016/j.cell.2024.02.041

DO - 10.1016/j.cell.2024.02.041

M3 - Review article

AN - SCOPUS:85188420233

SN - 0092-8674

VL - 187

SP - 1617

EP - 1635

JO - Cell

JF - Cell

IS - 7

ER -